U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Martin Avenue Pharmacy, Inc. - 447940 - 10/16/2017
  1. Warning Letters

CLOSEOUT LETTER

Martin Avenue Pharmacy, Inc. MARCS-CMS 447940 —

Recipient:
Recipient Name
Thomas G. Marks
Recipient Title
President
Martin Avenue Pharmacy, Inc.
Martin Avenue Pharmacy

1247 Rickert Drive
Naperville, IL 60540
United States

Issuing Office:

United States

312-353-5863

 

   

Black HHS-Blue FDA Logo

 

Division of Pharmaceutical Quality Operations III
300 River Place, Suite 5900
Detroit, MI 48207
Telephone: (313) 393-8100
Fax: (313) 393-8139 
 
 

October 16, 2017

UPS Next Day

Roopinder Ahluwalia, PharmD
Pharmacist-in-Charge
Martin Avenue Pharmacy, Inc.
1247 Rickert Drive, Suite 100
Naperville, IL 60540

Dear Dr. Ahluwalia:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (ref: WL# CHI-3-15) dated March 18, 2015. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
 

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Nicholas F. Lyons
Director of Compliance
Division of Pharmaceutical Quality Operations III

Back to Top